This is a working overview of solid-phase synthesis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-24. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
==== Canaloplasty ==== Canaloplasty is a nonpenetrating procedure using microcatheter technology. To perform a canaloplasty, an incision is made into the eye to gain access to the Schlemm's canal, similarly to a viscocanalostomy. A microcatheter will circumnavigate the canal around the iris, enlarging the main drainage channel and its smaller collector channels through the injection of a sterile, gel-like material called viscoelastic. The catheter is then removed, and a suture is placed within the canal and tightened. By opening the canal, the pressure inside the eye may be relieved, although the reason is unclear, since the canal (of Schlemm) does not have any significant fluid resistance in glaucoma or healthy eyes. Long-term results are not available.
=== Genesis of the Israelite people === Biblically, the Israelites referred to the descendants of Israel, a view that was reinforced by Second Temple Judaism, although gentiles could fully assimilate into the Israelite community. They referred to themselves as the sons of Israel, which could possibly refer to peoplehood rather than blood descent, especially after Israel's biological family transitioned from a clan to a nation (Exodus 1:9). The Israelite identity is alternatively interpreted as being based on religious allegiance, especially through worship of Yahweh or 'covenantal circumcision'. There's also contentious evidence of Israelite tribal status being acquired through self-declared allegiance, residency within assigned tribal territory (Ezekiel 47:21–23) or forceful absorption by a greater Israelite tribe. Jason A. Staples argues that the Israelites referred to the northern Israelite tribes, especially in the Nevi'im, although it's also inclusive of the other tribes in other contexts. The Israelites trace their ancestors to Jacob, who in turn descended from Abraham. Abraham was formerly a native of Ur Kaśdim (Genesis 11:31), whose location is unknown. Some scholars argue that it is located in lower Mesopotamia whilst others locate it further north in upper Mesopotamia, around northern Syria or southeastern Turkey. Theologians suggest that Canaan always belonged to the Israelites but was initially usurped by the descendants of Canaan, resulting in their conquest by Israel as divine punishment.
=== Leasing and sale of public lands === The law requires the leasing of at least 50% of public lands that private companies desire to lease for drilling, mining or logging. It cuts the royalties (the share of revenue) that the petroleum industry has had to pay for oil and gas extracted from public lands—costing taxpayers around $6 billion over a decade. It cuts the fee per acre that oil and gas companies have had to pay for initiating leasing of public lands. The law reinstates "noncompetitive leasing" of public lands for drilling, mining or logging that allows companies to purchase at a cheap price public lands that were not sold at auction. Over the next decade, the law requires four lease sales to oil and gas companies of lands inside Arctic National Wildlife Refuge, and six lease sales in the National Petroleum Reserve-Alaska along Alaska's northern coast. The law requires the Bureau of Land Management to hold quarterly onshore oil and gas lease sales.
Sources: en.wikipedia.org
F−H···F− (161.5 kJ/mol (38.6 kcal/mol)), illustrated uniquely by HF2- O−H···N (29 kJ/mol (6.9 kcal/mol)), illustrated water-ammonia O−H···O (21 kJ/mol (5.0 kcal/mol)), illustrated water-water, alcohol-alcohol N−H···N (13 kJ/mol (3.1 kcal/mol)), illustrated by ammonia-ammonia N−H···O (8 kJ/mol (1.9 kcal/mol)), illustrated water-amide OH+3···OH2 (18 kJ/mol (4.3 kcal/mol)) The strength of intermolecular hydrogen bonds is most often evaluated by measurements of equilibria between molecules containing donor and/or acceptor units, most often in solution. The strength of intramolecular hydrogen bonds can be studied with equilibria between conformers with and without hydrogen bonds. The most important method for the identification of hydrogen bonds also in complicated molecules is crystallography, sometimes also NMR-spectroscopy. Structural details, in particular distances between donor and acceptor which are smaller than the sum of the van der Waals radii can be taken as indication of the hydrogen bond strength. One scheme gives the following somewhat arbitrary classification: those that are 63 to 167 kJ/mol (15 to 40 kcal/mol), 21 to 63 kJ/mol (5 to 15 kcal/mol), and 0 to 21 kJ/mol (0 to 5 kcal/mol) are considered strong, moderate, and weak, respectively. Hydrogen bonds involving C−H bonds are both very rare and weak.
Originally Vogt developed the technique as a method for the introduction of large sample volumes (up to 250 μL) in capillary GC. Vogt introduced the sample into the liner at a controlled injection rate. The temperature of the liner was chosen slightly below the boiling point of the solvent. The low-boiling solvent was continuously evaporated and vented through the split line. Based on this technique, Poy developed the programmed temperature vaporising injector; PTV. By introducing the sample at a low initial liner temperature many of the disadvantages of the classic hot injection techniques could be circumvented. Gas source inlet or gas switching valve – gaseous samples in collection bottles are connected to what is most commonly a six-port switching valve. The carrier gas flow is not interrupted while a sample can be expanded into a previously evacuated sample loop. Upon switching, the contents of the sample loop are inserted into the carrier gas stream. P/T (purge-and-trap) system – An inert gas is bubbled through an aqueous sample causing insoluble volatile chemicals to be purged from the matrix. The volatiles are 'trapped' on an absorbent column (known as a trap or concentrator) at ambient temperature. The trap is then heated and the volatiles are directed into the carrier gas stream. Samples requiring preconcentration or purification can be introduced via such a system, usually hooked up to the S/SL port. The choice of carrier gas (mobile phase) is important. Hydrogen has a range of flow rates that are comparable to helium in efficiency.
==== Animal restraint ==== Large ranches and farms will generally use a squeeze chute to contain animals during branding. Livestock response to freeze branding is often so muted that ranchers report one leg restraint as being more than enough. Horse freeze branding is often accomplished with no more restraint than a twitch. This is a very different scenario from hot branding, where animals are often tied by all four legs to the bars of their squeeze chute to prevent the flight response from causing a misbrand.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.